Î³Î´ T cells and epigenetic drugs: A useful merger in cancer immunotherapy?

Bhat, Jaydeep; Kabelitz, Dieter.

Afiliação

Bhat J; Institute of Immunology; University of Kiel and UKSH Campus Kiel ; Kiel, Germany.
Kabelitz D; Institute of Immunology; University of Kiel and UKSH Campus Kiel ; Kiel, Germany.

Oncoimmunology ; 4(6): e1006088, 2015 Jun.

Article em En | MEDLINE | ID: mdl-26155411

Palavras-chave

DNMTi, DNA methyltransferase inhibitor(s); HDACi, histone deacetylase inhibitor(s); IL-2, interleukin-2; N-BP, nitrogen-containing bisphosphonate; NKG2D, natural killer group 2 member D; NSCLC, non-small cell lung cancer; epigenetic drugs; histone deacetylase inhibitor; immunotherapy; tumor cell; Î³Î´ T cells

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2015 Tipo de documento: Article